109 related articles for article (PubMed ID: 7670225)
21. Evaluation of potentially achievable vaccination coverage of the second dose of measles containing vaccine with simultaneous administration and risk factors for missed opportunities among children in Zhejiang province, east China.
Hu Y; Chen Y; Wang Y; Liang H
Hum Vaccin Immunother; 2018 Apr; 14(4):875-880. PubMed ID: 29252094
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
23. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age.
De Serres G; Boulianne N; Defay F; Brousseau N; Benoît M; Lacoursière S; Guillemette F; Soto J; Ouakki M; Ward BJ; Skowronski DM
Clin Infect Dis; 2012 Aug; 55(3):394-402. PubMed ID: 22543023
[TBL] [Abstract][Full Text] [Related]
24. [Guidelines for vaccination against measles in children].
Avila-Figueroa C; Navarrete-Navarro S; Santos JI
Bol Med Hosp Infant Mex; 1990 Jul; 47(7):528-33. PubMed ID: 2206422
[TBL] [Abstract][Full Text] [Related]
25. Consequences of delayed measles vaccination in Germany.
Siedler A; Hermann M; Schmitt HJ; Von Kries R
Pediatr Infect Dis J; 2002 Sep; 21(9):826-30. PubMed ID: 12352803
[TBL] [Abstract][Full Text] [Related]
26. Progress towards measles elimination in Singapore.
Ho HJ; Low C; Ang LW; Cutter JL; Tay J; Chan KP; Ooi PL; Thoon KC; Goh KT
Vaccine; 2014 Dec; 32(51):6927-6933. PubMed ID: 25444818
[TBL] [Abstract][Full Text] [Related]
27. Immunity against measles in populations of women and infants in Poland.
Janaszek W; Slusarczyk J
Vaccine; 2003 Jun; 21(21-22):2948-53. PubMed ID: 12798638
[TBL] [Abstract][Full Text] [Related]
28. Comparison of protection afforded by single measles vaccination and late revaccination schedules.
Marufu T; Siziya S; Tshimanga M; Murugasampillay S; Mason E
East Afr Med J; 1997 Dec; 74(12):777-9. PubMed ID: 9557421
[TBL] [Abstract][Full Text] [Related]
29. Predicting the impact of measles vaccination in England and Wales: model validation and analysis of policy options.
Babad HR; Nokes DJ; Gay NJ; Miller E; Morgan-Capner P; Anderson RM
Epidemiol Infect; 1995 Apr; 114(2):319-44. PubMed ID: 7705494
[TBL] [Abstract][Full Text] [Related]
30. Measles: not just another viral exanthem.
Duke T; Mgone CS
Lancet; 2003 Mar; 361(9359):763-73. PubMed ID: 12620751
[TBL] [Abstract][Full Text] [Related]
31. The role of herd immunity in control of measles.
Black FL
Yale J Biol Med; 1982; 55(3-4):351-60. PubMed ID: 7180027
[TBL] [Abstract][Full Text] [Related]
32. Maintaining high rates of measles immunization in Africa.
Lessler J; Moss WJ; Lowther SA; Cummings DA
Epidemiol Infect; 2011 Jul; 139(7):1039-49. PubMed ID: 20920382
[TBL] [Abstract][Full Text] [Related]
33. Uptake of measles containing vaccines in the measles, mumps, and rubella second dose catch-up programme in Wales.
Thomas DR; King J; Evans MR; Salmon RL
Commun Dis Public Health; 1998 Mar; 1(1):44-7. PubMed ID: 9718839
[TBL] [Abstract][Full Text] [Related]
34. Waning immunity and subclinical measles infections in England.
Glass K; Grenfell BT
Vaccine; 2004 Sep; 22(29-30):4110-6. PubMed ID: 15364464
[TBL] [Abstract][Full Text] [Related]
35. Seroconversion after measles vaccination at nine and fifteen months of age.
Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
[TBL] [Abstract][Full Text] [Related]
36. Measles, mumps and rubella: control by vaccination.
van Druten JA; de Boo T; Plantinga AD
Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
[TBL] [Abstract][Full Text] [Related]
37. Letter to the editor. Spotlight on measles 2010: timely administration of the first dose of measles vaccine in the context of an ongoing measles outbreak in France.
Gagneur A; Pinquier D
Euro Surveill; 2010 Oct; 15(41):19689; author reply 19686. PubMed ID: 20961512
[No Abstract] [Full Text] [Related]
38. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
39. Modelling the incidence of measles in Canada: an assessment of the options for vaccination policy.
Gay NJ; Pelletier L; Duclos P
Vaccine; 1998 May; 16(8):794-801. PubMed ID: 9627936
[TBL] [Abstract][Full Text] [Related]
40. Measles vaccination coverage, determinants of delayed vaccination and reasons for non-vaccination among children aged 24-35 months in Zhejiang province, China.
Hu Y; Wang Y; Chen Y; Liang H; Chen Z
BMC Public Health; 2018 Nov; 18(1):1298. PubMed ID: 30482185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
